FDA panel clashes with scientists over loosening peptide drug rules

An FDA advisory panel has recommended loosening restrictions on the compounding of six out of seven peptides, despite concerns raised by agency scientists regarding their safety and efficacy. The panel, which included members who sell experimental peptides, voted to allow specialty pharmacies to use these largely unregulated peptide treatments in custom medications. While the FDA typically considers panel recommendations, the internal opposition from its own scientists creates uncertainty about the final decision, especially given historical warnings against unapproved peptides due to limited human trial data and potential risks. AI

RANK_REASON Policy decision by a regulatory body's advisory panel that conflicts with agency scientists, impacting drug regulation. [lever_c_demoted from significant: ic=1 ai=0.1]

Read on Forbes — Innovation →

• American Medical Association
• BPC-157
• MedPage Today
• Partnership for Safe Medicines
• Pharmaceutical Compounding Advisory Committee
• Robert F. Kennedy Jr.
• STAT News
• Trump administration
• United States Food and Drug Administration

• policy
• other

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →